

September 2013 Half Year Results

25 November 2013



Important notice and disclaimer



- This presentation has been prepared by ALS Limited, (ALS or the Company). It contains general information about the Company's activities as at the date of the presentation. It is information given in summary form and does not purport to be complete. The distribution of this presentation in jurisdictions outside Australia may be restricted by law, and you should observe any such restrictions.
- This presentation is not, and nothing in it should be construed as, an offer, invitation or recommendation in respect of securities, or an offer, invitation or recommendation to sell, or a solicitation of an offer to buy, securities in any jurisdiction. Neither this document nor anything in it shall form the basis of any contract or commitment. This presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any investor. All investors should consider such factors in consultation with a professional advisor of their choosing when deciding if an investment is appropriate.
- The Company has prepared this presentation based on information available to it, including information derived from public sources that have not been independently verified. No representation or warranty, express or implied, is provided in relation to the fairness, accuracy, correctness, completeness or reliability of the information, opinions or conclusions expressed herein.
- This presentation may include forward-looking statements within the meaning of securities laws. Any forward-looking statements involve known and unknown risks and uncertainties, many of which are outside the control of the Company and its representatives. Forward-looking statements may also be based on estimates and assumptions with respect to future business decisions, which are subject to change. Any statements, assumptions, opinions or conclusions as to future matters may prove to be incorrect, and actual results, performance or achievement may vary materially from any projections and forward-looking statements.
- Due care and attention should be undertaken when considering and analysing the financial performance of the Company.
- All references to dollars are to Australian currency unless otherwise stated.

September 2013 Half Year Summary



half year	H1 FY13 (\$mn)	H2 FY13 (\$mn)	H1 FY14 (\$mn)
Revenue	813.6	685.7	744.7
EBITDA ¹	227.5	178.5	178.7
EBITDA ^{1,2} from continuing operations	223.4	178.5	178.7
Gain on sale of discontinued operations	5.8	0.1	0
Impairment	(6.1)	(10.0)	0
EBIT ¹	200.2	150.1	143.8
NPAT	135.5	91.8	97.7
EPS ³ (basic - cents per share)	39.3	26.7	27.1
Dividend (cents per share)	21	27	19


¹ Excludes gain on sale of discontinued operations and impairment loss

² EBITDA from continuing operations post the sale of the Chemical Division (Deltrex and Panamex)

³ Restated for impact of 1:11 renounceable rights issue undertaken in July 2013


September 2013 Half Year Trend





Operating Profit (EBIT) Diversification






Note: Chemical Division ("Chemical") divested during Sep-12 half year


Strategy - Revenue Growth and Diversification






Revenue - Market and Geography





CAPEX and **Depreciation**





■ CAPEX (exl. property purchases) ■ Depreciation & Amortisation


Revenue Growth




ALS Group Revenue Growth

- Organic Growth -16%
- Divestments -5%
- Acquired Growth +10%
- Currency Impact +3%

Reported Growth -8%



Revenue Growth H1 FY14 Vs H1 FY13



Life Sciences Division



	H1 FY14	H1 FY13	Change
Revenue	\$272mn	\$225mn	+21%
EBITDA	\$69mn	\$58mn	+19%
EBIT	\$54mn	\$47mn	+15%
EBIT Margin	19.6%	21.0%	-140 bps




- Organic revenue growth (9%) in Asia
- Organic revenue growth (10%) in mainland
 Europe
- Organic revenue growth (18%) in Scandinavia
- Margin improvement (80bps) in North America
- South America underperforming but improving
- Pricing pressure in Australia but significant project wins
- Food strategy implemented "building blocks" in place, focus now on growth
- New laboratories under construction
 - Copenhagen (Denmark)
- Consumer Products Testing business performing to expectation

Minerals Division



	H1 FY14	H1 FY13	Change
Revenue	\$232mn	\$345mn	-33%
EBITDA	\$75mn	\$137mn	-45%
EBIT	\$63mn	\$127mn	-50%
EBIT Margin	27.1%	36.7%	-960 bps




- Geochemistry
 - All markets remain weak especially West
 Africa, Canada and South America
 - Global sample volumes stable for last four months
 - Some localized pricing pressure
 - Hub & Spoke levers maintaining margins within expected range of 26% to 32%
- Metallurgy
 - North America reasonable
 - Challenging market in Australia
 - Pilot plants underutilized
 - Revenue down 37%
 - New Santiago (Chile) facility now operational
- Inspection
 - Revenue +16%
 - Margin >20% following losses H1 FY13
 - Further improvement to come

Industrial Division



	H1 FY14	H1 FY13	Change
Revenue	\$89mn	\$86mn	+4%
EBITDA	\$16mn	\$18mn	-11%
EBIT	\$14mn	\$16mn	-13%
EBIT Margin	15.3%	18.4%	-310 bps




- Asset Care
 - Scheduled outage inspection/maintenance postponements – especially higher margin Power Generation work
 - Lower margins due to mobilization problems at Gladstone LNG projects - now resolved
 - Decrease in "jobbing" market and pricing pressures
 - Successful relocation to new Brisbane site
 - Successful implementation of Osprey "LIMS"
- Tribology
 - Revenue growth of 8%
 - · Market share increase in mining
 - Some pricing pressure in Australia
 - Significant improvement in North America
 - Revenue +4%
 - Margin +340bps
 - Successful acquisition of OilCheck

Energy Division




	H1 FY14	H1 FY13	Change
Revenue	\$91mn	\$53mn	+70%
EBITDA	\$27mn	\$18mn	+50%
EBIT	\$22mn	\$17mn	+29%
EBIT Margin	24.2%	30.9%	-670 bps



- Coal
 - Close to bottom of cycle exploration activity to pick up in late CY14
 - Australian production and export levels at record high
 - Five new on-site production labs in place over last 12 months
 - Pricing pressure globally
 - Current margins remain >20%
 - Significantly restructured cost base
- Oil & Gas
 - Acquired Reservoir Group in August 2013
 - Acquired EarthData in July 2013
 - Acquisitions performing to plan
 - Lab strategy well advanced
 - Brisbane lab completed
 - Recruited Mark Beach global executive for ALS Oil & Gas lab business
 - Further acquisitions planned


Divisional and Business Stream Structure





Revenue Growth and Margin Strength





EBITDA Margin for SGS, Intertek, Bureau Veritas & Eurofins is for Half Year Ending June 2013 actual, and for Core Labs 9 months ending September 2013.

EBITDA Margin & Revenue for ALS excludes non-laboratory businesses but does include all corporate expenses..